Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | NOS2 | P35228 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NOS3 | P29474 | 1/20 | 0.57 |
| ▸ | NOS1 | P29475 | 1/20 | 0.57 |
| ▸ | KARS1 | Q15046 | 5/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | LTK | P29376 | 1/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912518 | 0.84 | KDR (0.57) | KDM4ENOS2MEN1KMT2ANOS3 | |
| SCHEMBL31247411 | 0.81 | NPC1 (0.50) | KDM4ENOS2MEN1KMT2ANOS3 | |
| SCHEMBL27606961 | 0.79 | GSK3A (0.48) | KDM4ENOS2MEN1KMT2ANOS3 | |
| SCHEMBL29919700 | 0.79 | SCN9A (0.53) | KDRCDK5CDK1CCNB1CCNA2 | |
| SCHEMBL28936140 | 0.79 | SCN9A (0.53) | KDRCDK5CDK1CCNB1CCNA2 | |
| SCHEMBL13064955 | 0.76 | CDK5 (0.61) | MEN1KMT2ACDK5CLK4CDK1 | |
| SCHEMBL8798667 | 0.76 | EGFR (0.61) | KDM4ECDK5ABL1CDK1CCNB1 | |
| SCHEMBL28038987 | 0.74 | HSP90AA1 (0.54) | KDRCDK5FYNGSK3ACDK9 | |
| SCHEMBL5750559 | 0.74 | KDR (0.56) | KDM4ENOS2MEN1KMT2AKARS1 | |
| SCHEMBL29406785 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719394-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ATOMWISE INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12358904-B2 | Inhibitors of TYK2 | Atomwise Inc. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240425484-A1 | INHIBITORS OF TYK2 | Atomwise Inc. | 2024-12-26 | — | — | US | disclosed |
| US-20240417396-A1 | INHIBITORS OF TYK2 | Atomwise Inc. | 2024-12-19 | — | — | US | disclosed |
| WO-2024250010-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417396-A1 | INHIBITORS OF TYK2 | TYK2, LCK, JAK2 | KDM4E 302/4885NOS2 3388/4885MEN1 2677/4885 |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | TYK2, FRK, DYRK2 | KDM4E 642/4885NOS2 1750/4885MEN1 4264/4885 |
| US-12358904-B2 | Inhibitors of TYK2 | TYK2, LCK, JAK2 | KDM4E 302/4885NOS2 3388/4885MEN1 2677/4885 |
| US-20240425484-A1 | INHIBITORS OF TYK2 | TYK2, LCK, JAK2 | KDM4E 302/4885NOS2 3388/4885MEN1 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.